Results showed improved metabolic indices with low dextrose solutions however association with adverse events due to extracellular volume expansion, raising the concern for uncontrolled volume status in the intervention group.45 In another trial, randomization to icodextrin (n=30) or dextrose (29) based PD solutions for the long dwell in diabetic patients on CAPD with high-average peritoneal transport rate lead to reduced glucose absorption, insulin necessity, as well as fasting blood glucose and triglyceride levels, suggesting that reduced peritoneal absorption of glucose improved metabolic control
Not every peptide program is appropriate for every patient
Moreover, the preference for innovative and less invasive treatment options aligns well with the ongoing development of oral and long-acting formulations
Ipamorelin: ipamorelin's safety has not been tested extensively in clinical settings, and the largest human study so far was a phase-2 trial with 114 subjects that lasted only 7 days
The peptide does not appear to require cycling for maintained effectiveness, though many users prefer periodic breaks as a precautionary measure
